D형 간염 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에는 CAGR4.4%로 9억 달러로 성장할 전망입니다. 예측 기간의 성장은 새로운 치료법에 대한 환급 정책의 확대, 의료 부문에 대한 투자 증가, 병용 치료법의 채택 증가, B형 간염 백신 접종 범위 확대, 공중 보건 노력 증가에 기인할 수 있습니다. 주요 트렌드에는 분자 진단 도구의 발전, 간 질환 관리를 위한 개인 맞춤형 의학으로의 전환, 새로운 RNA 기반 치료법의 개발, D형 간염 치료제의 임상시험 확대, 간염 관리를 위한 원격 의료의 사용 증가 등이 있습니다.
B형 간염의 유병률 증가는 향후 몇 년 동안 D형 간염 시장의 성장을 견인할 것으로 예상됩니다. B형 간염은 간에 영향을 미치는 바이러스 감염으로 황달, 피로, 복통 등의 증상을 유발하며 치료하지 않고 방치하면 만성 간 질환이나 간암으로 이어질 수 있습니다. B형 간염 사례의 증가는 보호되지 않은 성 접촉, 주사기 공유, 출산 중 산모와 아이 사이의 전염, 특정 지역의 불충분한 백신 접종 범위와 같은 요인에 기인합니다. D형 간염은 표면 항원을 사용하여 간세포를 감염시키는 B형 간염 바이러스에 의존하여 복제하므로 두 바이러스의 동시 감염은 간 질환 진행의 중요한 요인입니다. 예를 들어, 2023년 11월 미국 보건복지부는 2022년에 새로 보고된 만성 B형 간염 사례가 전년도에 비해 11% 증가했다고 보고했습니다. 결과적으로 B형 간염의 유병률 증가는 D형 간염 시장의 확장을 촉진하고 있습니다.
D형 간염 시장을 선도하는 기업들은 면역 효과를 개선하고 바이러스에 대한 장기적인 예방 효과를 제공하기 위해 재조합 백신과 같은 혁신적인 제형 개발에 주력하고 있습니다. 재조합 백신은 바이러스 단백질을 암호화하는 유전자를 박테리아나 효모와 같은 숙주 유기체에 삽입하여 질병을 일으키지 않고 면역 반응을 자극하는 단백질 생산을 가능하게 하는 방식으로 생산됩니다. 예를 들어, 2022년 12월, 미국에 본사를 둔 생명공학 회사인 VBI 백신은 캐나다 보건부로부터 18세 이상 성인에서 알려진 모든 아형의 B형 간염에 대한 예방 백신인 프리헤브리오[3항원 B형 간염 백신(재조합)]에 대한 승인을 받았습니다. 이번 승인은 D형 간염의 원인이 되는 델타 항원은 B형 간염 감염 없이는 존재할 수 없기 때문에 D형 간염 예방에도 확대 적용됩니다. 이번 결정은 단일 항원 엔게릭스-B 백신에 비해 프리헤브리오의 혈청 보호율이 더 높은 것으로 입증된 두 개의 중추적인 3상 임상 연구인 PROTECT와 CONSTANT의 긍정적인 결과를 바탕으로 이루어졌습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 D형 간염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 D형 간염 시장 : 성장률 분석
- 세계의 D형 간염 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 D형 간염 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 D형 간염 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 D형 간염 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 급성
- 만성
- 세계의 D형 간염 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 혈액검사
- 탄성 검사
- 간 생검
- 혈청 검사
- 기타 진단
- 세계의 D형 간염 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 세계의 D형 간염 시장 : 최종사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 클리닉
- 병원
- 기타 최종 사용자
- 세계의 D형 간염 시장 : 급성 질환 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 자가 제한 급성 D형 간염
- 중증 급성 D형 간염
- 세계의 D형 간염 시장 : 만성 질환 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 보상성 만성 D형 간염
- 비보상성 만성 D형 간염
제7장 지역별 및 국가별 분석
- 세계의 D형 간염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 D형 간염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- D형 간염 시장 : 경쟁 구도
- D형 간염 시장 : 기업 프로파일
- F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
- Abbott Laboratories 개요, 제품 및 서비스, 전략 및 재무 분석
- GSK plc 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Gilead Sciences Inc.
- Viatris Inc
- VBI Vaccines Inc
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Dynavax Technologies Corporation
- Echosens SA
- Arbutus Biopharma Corporation
- PROBIOMED SA de CV
- Assembly Biosciences Inc.
- Replicor Inc.
- Eiger BioPharmaceuticals Inc
- Bluejay Therapeutics Inc
- Janssen Pharmaceuticals Inc.
- Transgene SA
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- D형 간염 시장(2029년) : 새로운 기회를 제공하는 국가
- D형 간염 시장(2029년) : 새로운 기회를 제공하는 부문
- D형 간염 시장(2029년) : 성장 전략
제36장 부록
HBR
Hepatitis D, also referred to as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is regarded as the most severe form of viral hepatitis and occurs exclusively in individuals already infected with the hepatitis B virus (HBV). The hepatitis D virus relies on the hepatitis B virus for replication and survival, making it either a co-infection or a superinfection.
The primary types of hepatitis D are acute and chronic. Acute hepatitis D is a sudden and severe liver infection caused by the hepatitis D virus, often leading to rapid-onset symptoms and potential liver complications. Diagnosis is conducted through various methods, including blood tests, elastography, liver biopsy, serologic testing, and other diagnostic techniques. Medications for hepatitis D are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, including clinics, hospitals, and other healthcare facilities.
The hepatitis D market research report is one of a series of new reports from The Business Research Company that provides hepatitis D market statistics, including the hepatitis D industry global market size, regional shares, competitors with the hepatitis D market share, detailed hepatitis D market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis D industry. This hepatitis D market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hepatitis D market size has grown steadily in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth during the historic period can be attributed to limited treatment options, a high prevalence in endemic regions, co-infection with hepatitis B, low awareness and diagnosis rates, and government vaccination programs.
The hepatitis D market size is expected to see steady growth in the next few years. It will grow to $0.90 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to the expansion of reimbursement policies for novel therapies, rising investment in the healthcare sector, increasing adoption of combination treatments, greater hepatitis B vaccination coverage, and growing public health initiatives. Key trends include advancements in molecular diagnostic tools, a shift toward personalized medicine for liver disease management, the development of novel RNA-based therapies, the expansion of clinical trials for hepatitis D treatments, and the increasing use of telemedicine for hepatitis management.
The rising prevalence of hepatitis B is expected to drive the growth of the hepatitis D market in the coming years. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increasing number of hepatitis B cases is attributed to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Hepatitis D depends on the hepatitis B virus for replication, using its surface antigen to infect liver cells, making co-infection with both viruses a significant factor in liver disease progression. For example, in November 2023, the US Department of Health and Human Services reported an 11% rise in newly reported chronic hepatitis B cases in 2022 compared to the previous year. As a result, the growing prevalence of hepatitis B is fueling the expansion of the hepatitis D market.
Leading companies in the hepatitis D market are focusing on developing innovative formulations such as recombinant vaccines to improve immunization efficacy and provide long-lasting protection against the virus. Recombinant vaccines are produced by inserting a gene encoding a viral protein into a host organism, such as bacteria or yeast, allowing the production of the protein to stimulate an immune response without causing the disease. For instance, in December 2022, VBI Vaccines Inc., a US-based biotechnology company, received approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], a vaccine for active immunization against all known subtypes of hepatitis B in adults aged 18 and older. This approval also extends to hepatitis D prevention, as the delta agent responsible for hepatitis D cannot exist without a hepatitis B infection. The decision was based on positive results from two pivotal Phase 3 clinical studies, PROTECT and CONSTANT, which demonstrated higher seroprotection rates with PreHevbrio compared to the single-antigen Engerix-B vaccine.
In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to advance the development of next-generation antiviral therapies. This collaboration aims to create innovative treatments for serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences Inc. is a US-based biotechnology company specializing in the development of small-molecule therapeutics targeting serious viral diseases, particularly hepatitis B virus (HBV) and herpes viruses.
Major players in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, and Biorex Diagnostics Ltd.
North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis D report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hepatitis D market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hepatitis D market consists of revenues earned by entities by providing services such as clinical and diagnostic services, public health and awareness campaigns, research and development services, or treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis D market also includes sales of antiviral drugs, interferon therapies, nucleic acid polymers, liver transplant services, and diagnostic tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hepatitis D Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hepatitis d market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hepatitis d ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis d market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Acute; Chronic
- 2) By Diagnosis: Blood Tests; Elastography; Liver Biopsy; Serologic Testing; Other Diagnosis
- 3) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online Pharmacies
- 4) By End-Users: Clinic; Hospital; Other End Users
- Subsegments:
- 1) By Acute: Self-limiting Acute Hepatitis D; Severe Acute Hepatitis D
- 2) By Chronic: Compensated Chronic Hepatitis D; Decompensated Chronic Hepatitis D
- Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bristol-Myers Squibb Company; Abbott Laboratories; GSK plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Hepatitis D Market Characteristics
3. Hepatitis D Market Trends And Strategies
4. Hepatitis D Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Hepatitis D Growth Analysis And Strategic Analysis Framework
- 5.1. Global Hepatitis D PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Hepatitis D Market Growth Rate Analysis
- 5.4. Global Hepatitis D Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Hepatitis D Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Hepatitis D Total Addressable Market (TAM)
6. Hepatitis D Market Segmentation
- 6.1. Global Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Acute
- Chronic
- 6.2. Global Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Blood Tests
- Elastography
- Liver Biopsy
- Serologic Testing
- Other Diagnosis
- 6.3. Global Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital pharmacies
- Retail pharmacies
- Online Pharmacies
- 6.4. Global Hepatitis D Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Clinic
- Hospital
- Other End Users
- 6.5. Global Hepatitis D Market, Sub-Segmentation Of Acute, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Self-limiting Acute Hepatitis D
- Severe Acute Hepatitis D
- 6.6. Global Hepatitis D Market, Sub-Segmentation Of Chronic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Compensated Chronic Hepatitis D
- Decompensated Chronic Hepatitis D
7. Hepatitis D Market Regional And Country Analysis
- 7.1. Global Hepatitis D Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Hepatitis D Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Hepatitis D Market
- 8.1. Asia-Pacific Hepatitis D Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hepatitis D Market
- 9.1. China Hepatitis D Market Overview
- 9.2. China Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hepatitis D Market
- 10.1. India Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hepatitis D Market
- 11.1. Japan Hepatitis D Market Overview
- 11.2. Japan Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hepatitis D Market
- 12.1. Australia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hepatitis D Market
- 13.1. Indonesia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hepatitis D Market
- 14.1. South Korea Hepatitis D Market Overview
- 14.2. South Korea Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hepatitis D Market
- 15.1. Western Europe Hepatitis D Market Overview
- 15.2. Western Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hepatitis D Market
- 16.1. UK Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Hepatitis D Market
- 17.1. Germany Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hepatitis D Market
- 18.1. France Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Hepatitis D Market
- 19.1. Italy Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Hepatitis D Market
- 20.1. Spain Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hepatitis D Market
- 21.1. Eastern Europe Hepatitis D Market Overview
- 21.2. Eastern Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hepatitis D Market
- 22.1. Russia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hepatitis D Market
- 23.1. North America Hepatitis D Market Overview
- 23.2. North America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hepatitis D Market
- 24.1. USA Hepatitis D Market Overview
- 24.2. USA Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Hepatitis D Market
- 25.1. Canada Hepatitis D Market Overview
- 25.2. Canada Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hepatitis D Market
- 26.1. South America Hepatitis D Market Overview
- 26.2. South America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hepatitis D Market
- 27.1. Brazil Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hepatitis D Market
- 28.1. Middle East Hepatitis D Market Overview
- 28.2. Middle East Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hepatitis D Market
- 29.1. Africa Hepatitis D Market Overview
- 29.2. Africa Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hepatitis D Market Competitive Landscape And Company Profiles
- 30.1. Hepatitis D Market Competitive Landscape
- 30.2. Hepatitis D Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis
31. Hepatitis D Market Other Major And Innovative Companies
- 31.1. Gilead Sciences Inc.
- 31.2. Viatris Inc
- 31.3. VBI Vaccines Inc
- 31.4. Alnylam Pharmaceuticals Inc.
- 31.5. Arrowhead Pharmaceuticals Inc.
- 31.6. Dynavax Technologies Corporation
- 31.7. Echosens S.A
- 31.8. Arbutus Biopharma Corporation
- 31.9. PROBIOMED SA de CV
- 31.10. Assembly Biosciences Inc.
- 31.11. Replicor Inc.
- 31.12. Eiger BioPharmaceuticals Inc
- 31.13. Bluejay Therapeutics Inc
- 31.14. Janssen Pharmaceuticals Inc.
- 31.15. Transgene SA
32. Global Hepatitis D Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Hepatitis D Market
34. Recent Developments In The Hepatitis D Market
35. Hepatitis D Market High Potential Countries, Segments and Strategies
- 35.1 Hepatitis D Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Hepatitis D Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Hepatitis D Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
